Archive

« Older Entries

Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable C... Wednesday, December 27th, 2017
UTRECHT, The Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]
Kiadis CEO interviewed by the Dutch financial radio station BNR Thursday, December 21st, 2017
Good afternoon, As we continue to make significant operational progress at Kiadis, we have also been working to raise Kiadis’ profile through investor events, conference attendance and media outreach. Our CEO Arthur [...]
argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering Thursday, December 14th, 2017
Regulated information - Inside information     Breda, the Netherlands / Ghent, Belgium, December 14, 2017 - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline [...]
LSP Raises EUR 280 Million to Invest In Healthcare Innovation Tuesday, December 12th, 2017
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe [...]
Immunic Therapeutics Successfully Completes two Phase 1 Studies for IMU-838 Tuesday, December 12th, 2017
Two phase 1 studies for IMU-838 in healthy volunteers have been completed Compound was safe and well tolerated at all doses tested New dosing regimen was determined allowing safe administration of high [...]
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis Monday, December 11th, 2017
Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study  75% of ARGX-113 treated p [...]
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hemat... Monday, December 11th, 2017
Workshop to be held on Monday, December 11th at 12:00 pm EST Breda, the Netherlands / Ghent, Belgium, December 11, 2017 - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep [...]
Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH Monday, December 11th, 2017
Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated; 3-month ORR compares favorably to historical ORR of pembrolizumab alone Additional preclinical data presented on BCMA-targe [...]
LSP leads EUR 27 mln Series A financing of new VIB start-up Aelin Therapeutics to exploit its proprietary Pept-in™ protein knockdown platform Monday, December 11th, 2017
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a EUR 27 million investment to pioneer a novel modality in drug develo [...]
LSP Partner Clemens van Blitterswijk gives a Tedx on the future of regenerative medicine Thursday, December 7th, 2017
The video is now online via the following link [...]

« Older Entries

2018
2017
2016
2015
2014
2013
2012
back to archive overview

Archive

« Older Entries

Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable... Wednesday, December 27th, 2017
UTRECHT, The Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]
Kiadis CEO interviewed by the Dutch financial radio station BNR Thursday, December 21st, 2017
Good afternoon, As we continue to make significant operational progress at Kiadis, we have also been working to raise Kiadis’ profile through investor events, conference attendance and media outreach. Our CEO Arthur [...]
argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering Thursday, December 14th, 2017
Regulated information - Inside information     Breda, the Netherlands / Ghent, Belgium, December 14, 2017 - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline [...]
LSP Raises EUR 280 Million to Invest In Healthcare Innovation Tuesday, December 12th, 2017
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe [...]
Immunic Therapeutics Successfully Completes two Phase 1 Studies for IMU-838 Tuesday, December 12th, 2017
Two phase 1 studies for IMU-838 in healthy volunteers have been completed Compound was safe and well tolerated at all doses tested New dosing regimen was determined allowing safe administration of high [...]
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis Monday, December 11th, 2017
Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study  75% of ARGX-113 treated p [...]
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hem... Monday, December 11th, 2017
Workshop to be held on Monday, December 11th at 12:00 pm EST Breda, the Netherlands / Ghent, Belgium, December 11, 2017 - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep [...]
Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH Monday, December 11th, 2017
Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated; 3-month ORR compares favorably to historical ORR of pembrolizumab alone Additional preclinical data presented on BCMA-targe [...]
LSP leads EUR 27 mln Series A financing of new VIB start-up Aelin Therapeutics to exploit its proprietary Pept-in™ protein knockdown platform Monday, December 11th, 2017
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a EUR 27 million investment to pioneer a novel modality in drug develo [...]
LSP Partner Clemens van Blitterswijk gives a Tedx on the future of regenerative medicine Thursday, December 7th, 2017
The video is now online via the following link [...]

« Older Entries

2018
2017
2016
2015
2014
2013
2012
back to archive overview